Meeting
2018 ASCO Annual Meeting
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
Authors
Kim Leitzel
Penn State Hershey Medical Center, Hershey, PA
Kim Leitzel , Suhail M. Ali , Lois E. Shepherd , Wendy R. Parulekar , Liting Zhu , Shakeel Virk , Dora Nomikos , Samuel Aparicio , Karen A. Gelmon , Joseph J. Drabick , Leah Cream , E Scott Halstead , Hyma Vani Polimera , Ashok Maddukuri , Aamnah Ali , Urmeel Hasmukh Patel , Joyson Poulose , Howard Spiegel , Bingshu E. Chen , Allan Lipton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1031)
DOI
10.1200/JCO.2018.36.15_suppl.1031
Abstract #
1031
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.
First Author: Prashanth Reddy Moku
Poster
2018 ASCO Annual Meeting
![A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].](https://d201v5jt9ylckg.cloudfront.net/214/12940/161815/161815_poster_pv.jpg)
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
First Author: Stephen K. L. Chia
Poster
2023 ASCO Annual Meeting
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.
First Author: Tanios S. Bekaii-Saab
Poster
2014 ASCO Annual Meeting
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
First Author: Diep Ho